Short answer
EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 8.01 (Other Events). Independent DSMC recommended continuation after the third scheduled review of DURAVYU’s pivotal Phase 3 wet AMD program.
EyePoint, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Independent DSMC recommended continuation after the third scheduled review of DURAVYU’s pivotal Phase 3 wet AMD program
- Positive safety oversight supports ongoing development and reduces immediate clinical-trial continuation concerns
- DURAVYU targets wet age-related macular degeneration, a major commercial opportunity if efficacy and regulatory milestones follow
- Full announcement details appear in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other EyePoint, Inc. 8-K filings
Get the next EYPT 8-K as it lands
Follow EYPT for push alerts, or ask the research agent what this filing means.